Work with thought leaders and academic experts in hematology
Companies can greatly benefit from collaborating with academic researchers in the field of Hematology. These experts bring a wealth of knowledge and experience that can enhance research, development, and innovation in various ways. Here are some key reasons why companies would want to collaborate with Hematology researchers: 1. Cutting-edge Research: Hematology researchers are at the forefront of scientific advancements in blood disorders and diseases. Collaborating with them can provide access to the latest research findings and breakthroughs. 2. Expertise in Clinical Trials: Hematology researchers have extensive experience in conducting clinical trials for new treatments and therapies. Partnering with them can accelerate the development and testing of new drugs. 3. Access to Specialized Equipment: Hematology researchers often have access to state-of-the-art equipment and facilities. Collaborating with them can provide companies with access to advanced technologies for research and development. 4. Collaboration on Publications: Working with Hematology researchers can lead to joint publications in reputable scientific journals. This can enhance the company's reputation and credibility in the field. 5. Networking Opportunities: Collaborating with Hematology researchers allows companies to expand their professional network and establish connections with other experts in the field. By collaborating with academic researchers in Hematology, companies can tap into a vast pool of knowledge and expertise, leading to improved research outcomes and potential commercial success.
Researchers on NotedSource with backgrounds in hematology include Dushani L. Palliyaguru, Ph.D., Ping Luo, Burcu Vitrinel, Ph.D., Dr. Everson A Nunes, Ph.D., Boris Leibovitch, John M Baust, Ph.D, Jeffrey Townsend, Khoa Nguyen, Dr. Matthias Steiert, Ph.D., Luke Connelly, Marina Baretti, Michael Cukan, and Ritika Rastogi, PhD.
Dushani L. Palliyaguru, Ph.D.
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Most Relevant Research Interests
Other Research Interests (16)
About
Most Relevant Publications (1+)
21 total publications
Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane
Seminars in Oncology / Feb 01, 2016
Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013
See Full Profile
Ping Luo
Bioinformatics Specialist at Princess Margaret Cancer Centre with experience in deep learning
Most Relevant Research Interests
Other Research Interests (21)
About
Most Relevant Publications (1+)
23 total publications
Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma
Blood / Nov 05, 2021
Coffey, D. G., Maura, F., Gonzalez-Kozlova, E., Diaz-Mejia3, J., Luo, P., Zhang, Y., Xu, Y., Warren, E. H., Smith, E. L., Cho, H. J., Lesokhin, A., Diamond, B., Kazandjian, D., Pugh, T. J., Green, D. J., Gnjatic, S., & Landgren, O. (2021). Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma. Blood, 138(Supplement 1), 329–329. https://doi.org/10.1182/blood-2021-154506
See Full Profile
Dr. Everson A Nunes, Ph.D.
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Interests
Other Research Interests (39)
About
Most Relevant Publications (1+)
97 total publications
Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms
Revista Brasileira de Hematologia e Hemoterapia / Jan 01, 2013
Betiati, D. da S. B., Oliveira, P. F. de, Camargo, C. de Q., Nunes, E. A., & Trindade, E. B. S. de M. (2013). Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms. Revista Brasileira de Hematologia e Hemoterapia, 35(2). https://doi.org/10.5581/1516-8484.20130033
See Full Profile
Boris Leibovitch
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Other Research Interests (8)
About
Most Relevant Publications (1+)
22 total publications
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Blood / Mar 15, 2008
Marango, J., Shimoyama, M., Nishio, H., Meyer, J. A., Min, D.-J., Sirulnik, A., Martinez-Martinez, Y., Chesi, M., Bergsagel, P. L., Zhou, M.-M., Waxman, S., Leibovitch, B. A., Walsh, M. J., & Licht, J. D. (2008). The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood, 111(6), 3145–3154. https://doi.org/10.1182/blood-2007-06-092122
See Full Profile
John M Baust, Ph.D
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Interests
Other Research Interests (16)
About
Most Relevant Publications (1+)
68 total publications
Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model
Cancer Control / Jan 01, 2018
Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control, 25(1), 107327481875741. https://doi.org/10.1177/1073274818757418
See Full Profile
Jeffrey Townsend
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Other Research Interests (52)
About
Most Relevant Publications (3+)
207 total publications
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia
Leukemia / Nov 11, 2022
Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Annals of Oncology / Jan 01, 2017
Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Annals of Oncology / Jan 01, 2017
Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436
See Full Profile
Khoa Nguyen
Life Sciences Expert with 18-Year Experience in Immunology, Metabolism, Neuroscience, and Biotech Entrepreuneuship
Most Relevant Research Interests
Other Research Interests (25)
About
Most Relevant Publications (1+)
47 total publications
Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways
Blood / Apr 07, 2011
Nguyen, K. D., Macaubas, C., Nadeau, K. C., Truong, P., Yoon, T., Lee, T., Park, J. L., & Mellins, E. D. (2011). Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways. Blood, 117(14), 3793–3798. https://doi.org/10.1182/blood-2010-11-318832
See Full Profile
Dr. Matthias Steiert, Ph.D.
Consultant with 30 years of interdisciplinary R&D experience in drug discovery and material sciences
Most Relevant Research Interests
Other Research Interests (27)
About
Most Relevant Publications (1+)
13 total publications
Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components
Transfusion / Jul 29, 2008
Grellier, P., Benach, J., Labaied, M., Charneau, S., Gil, H., Monsalve, G., Alfonso, R., Sawyer, L., Lin, L., Steiert, M., & Dupuis, K. (2008). Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion, 48(8), 1676–1684. Portico. https://doi.org/10.1111/j.1537-2995.2007.01762.x
See Full Profile
Luke Connelly
Professor of Health Economics, The University of Queensland, CBEH
Most Relevant Research Interests
Other Research Interests (42)
About
Most Relevant Publications (1+)
105 total publications
An economic evaluation of plasma production via erythroplasmapheresis and whole blood collection
Transfusion and Apheresis Science / Oct 01, 2002
Connelly, L. B., & Pink, A. (2002). An economic evaluation of plasma production via erythroplasmapheresis and whole blood collection. Transfusion and Apheresis Science, 27(2), 101–111. https://doi.org/10.1016/s1473-0502(02)00046-0
See Full Profile
Marina Baretti
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Other Research Interests (14)
About
Most Relevant Publications (22+)
57 total publications
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
Annals of Oncology / Mar 01, 2017
Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627
Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic
Cancer Control / Jan 01, 2021
Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945
Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
Annals of Oncology / Oct 01, 2016
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84
Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer
Annals of Oncology / Sep 01, 2014
Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48
Modified Folfoxiri in advanced Pancreatic Cancer
Annals of Oncology / Sep 01, 2012
Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0
TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)
Annals of Oncology / Sep 01, 2012
Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Annals of Oncology / Sep 01, 2021
Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797
Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram
Annals of Oncology / Sep 01, 2017
Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052
ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND
Annals of Oncology / Oct 01, 2015
Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59
SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus
Annals of Oncology / Oct 01, 2019
De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
Annals of Oncology / Oct 01, 2017
Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008
Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram
Annals of Oncology / Oct 01, 2017
Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008
Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study
Annals of Oncology / Oct 01, 2016
Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104
Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study
Annals of Oncology / Sep 01, 2016
Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29
An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort
Annals of Oncology / Sep 01, 2016
Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29
Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience
Annals of Oncology / Sep 01, 2016
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03
P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer
Annals of Oncology / Jun 01, 2016
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167
O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)
Annals of Oncology / Jun 01, 2016
Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13
Third-Line Folfiri in Metastatic Gastric Cancer Patients
Annals of Oncology / Sep 01, 2012
Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)
Annals of Oncology / Sep 01, 2012
Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3
See Full Profile
Michael Cukan
Bioconjugates, Analytical biochemistry method development
Most Relevant Research Interests
Other Research Interests (12)
About
Most Relevant Publications (1+)
11 total publications
KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab
Blood / Nov 05, 2020
Vidal, C., Cukan, M., Vaill, A., Bunin, A., Rossi, A. M., Iben, L., Trinh, D., McGrath, K., Berbasova, T., Romee, R., Alvarez, E., Rastelli, L., & Welsch, M. (2020). KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab. Blood, 136(Supplement 1), 9–10. https://doi.org/10.1182/blood-2020-142113
See Full Profile
Ritika Rastogi, PhD
Brigham & Women's Hospital
Most Relevant Research Interests
Other Research Interests (14)
Most Relevant Publications (1+)
8 total publications
A PDZ-Binding Motif in DCAF7 Maintains Hematopoietic Homeostasis and Prevents Malignancy in DS-AMKL
Blood / Dec 02, 2016
Kirsammer, G., Schultz, R. F., Rastogi, R., Gurbuxani, S., & Crispino, J. (2016). A PDZ-Binding Motif in DCAF7 Maintains Hematopoietic Homeostasis and Prevents Malignancy in DS-AMKL. Blood, 128(22), 1205–1205. https://doi.org/10.1182/blood.v128.22.1205.1205
See Full Profile
Example hematology projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on hematology?
Development of Novel Hematology Diagnostic Tool
A company in the medical device industry can benefit from collaborating with a Hematology researcher to develop a novel diagnostic tool for blood disorders. The researcher's expertise in analyzing blood samples and identifying specific markers can contribute to the development of an accurate and efficient diagnostic device.
Drug Discovery for Hematological Cancers
A pharmaceutical company focused on oncology can collaborate with a Hematology researcher to discover new drugs for hematological cancers. The researcher's deep understanding of the molecular mechanisms involved in blood cancers can guide the development of targeted therapies.
Improving Blood Transfusion Practices
A healthcare organization can partner with a Hematology researcher to improve blood transfusion practices. The researcher's knowledge of blood compatibility, transfusion reactions, and storage techniques can help optimize transfusion protocols and ensure patient safety.
Development of Gene Therapies for Hemophilia
A biotechnology company can collaborate with a Hematology researcher to develop gene therapies for hemophilia. The researcher's expertise in gene editing and delivery systems can contribute to the development of innovative treatments for this genetic blood disorder.
Exploring Stem Cell Therapies for Blood Disorders
A regenerative medicine company can work with a Hematology researcher to explore the potential of stem cell therapies for blood disorders. The researcher's knowledge of hematopoietic stem cells and their differentiation can aid in developing novel therapeutic approaches.